Fluoropyrimidine-induced cardiotoxicity

doi:10.5306/wjco.v11.i12.1008

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8016)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

510

WORD

280

HTML

4113

Figures (1-1)

282

Tables (1-1)

238

Sum=5423

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

300

Download

538

Sum=838

Publishing Process of This Article

Item

Count

Browse

666

Download

1089

Sum=1755

Dec 24, 2020 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Dec 24, 2020; 11(12): 1008-1017
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.1008

Fluoropyrimidine-induced cardiotoxicity

Andrada Larisa Deac, Claudia Cristina Burz, Ioana Corina Bocsan, Anca Dana Buzoianu

Andrada Larisa Deac, Department of Medical Oncology, "Prof.Dr.Ion Chiricuta" Oncology Institute from Cluj-Napoca, Cluj-Napoca 400015, Cluj, Romania

Claudia Cristina Burz, Department of Immunology and Allergology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca 400015, Cluj, Romania

Ioana Corina Bocsan, Anca Dana Buzoianu, Department of Pharmacology, Toxicology and Clinical Pharmacology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca 400015, Cluj, Romania

Author contributions: Deac AL performed the majority of the writing, designed the tables and figures; Deac AL, Burz CC, Bocsan IC, Buzoianu AD designed the study; Deac AL performed the research on medical literature; all authors have read and approved the final manuscript.

Conflict-of-interest statement: No conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Andrada Larisa Deac, MD, Doctor, Department of Medical Oncology, "Prof.Dr.Ion Chiricuta" Oncology Institute from Cluj-Napoca, Republicii Street, Cluj-Napoca 400015, Cluj, Romania. andrada.deac@gmail.com

Received: June 8, 2020
Peer-review started: June 8, 2020
First decision: September 18, 2020
Revised: September 27, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: December 24, 2020
Processing time: 192 Days and 24 Hours

Core Tip

Core Tip: There are several reviews and cases which showed fluoropyrimidine-induced cardiotoxicity. However, this mini-review includes useful information on clinical manifestations, pathophysiological mechanisms, diagnosis, and management of fluoropyrimidine-induced cardiotoxicity.